Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease

M. A. Wood, B. S. Stambler, K. A. Ellenbogen, D. M. Gilligan, K. T. Perry, L. K. Wakefield, J. T. VanderLugt, D. G. Benditt, J. P. DiMarco, D. Fitzgerald, P. R. Kowey, E. V. Platia, S. F. Schaal, E. Shen, Jr Wesley, John Robert Windle, M. A. Wood

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Recent studies suggest that class III antiarrhythmic agents may have enhanced efficacy in the treatment of ventricular tachycardia. This study describes the first clinical assessment of the new class III agent ibutilide to suppress inducible monomorphic ventricular tachycardia (VT) in human beings. Methods and Results: Fifty-five patients with coronary artery disease and inducible sustained monomorphic VT at baseline received either low (0.005 mg/kg + 0.001 mg/kg, load and maintenance infusion, respectively), middle (0.01 mg/kg + 0.002 mg/kg), or high dose (0.02 mg/kg + 0.004 mg/kg) infusions of ibutilide followed by repeat programmed ventricular stimulation. The mean age of the study group was 65.5 ± 9.5 years and mean left ventricular ejection fraction was 36% ± 11%. Of 48 evaluable patients, 21 (44%) were rendered noninducible after ibutilide, with no difference in efficacy among the three dosing groups (p = 0.83). Ventricular effective refractory periods, QTc interval, and ventricular monophasic action potential duration were prolonged over baseline at all tested cycle lengths. The QTc and action potential prolongation were dose related. Serious drug-related adverse reactions included sustained polymorphic VT in two patients (3.6%), spontaneous monomorphic VT in one patient (1.8%), heart block in one patient (1.8%), and hypotension in one patient (1.8%). Conclusions: Ibutilide prolongs ventricular repolarization in human beings and demonstrates efficacy in suppressing inducible monomorphic VT. Significant cardiovascular side effects occurred in 12.7% of patients.

Original languageEnglish (US)
Pages (from-to)1048-1054
Number of pages7
JournalAmerican Heart Journal
Volume135
Issue number6 I
DOIs
StatePublished - Jan 1 1998

Fingerprint

Ventricular Tachycardia
Coronary Artery Disease
Action Potentials
Heart Block
ibutilide
Drug-Related Side Effects and Adverse Reactions
Stroke Volume
Hypotension
Age Groups
Maintenance

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Wood, M. A., Stambler, B. S., Ellenbogen, K. A., Gilligan, D. M., Perry, K. T., Wakefield, L. K., ... Wood, M. A. (1998). Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. American Heart Journal, 135(6 I), 1048-1054. https://doi.org/10.1016/S0002-8703(98)70071-7

Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. / Wood, M. A.; Stambler, B. S.; Ellenbogen, K. A.; Gilligan, D. M.; Perry, K. T.; Wakefield, L. K.; VanderLugt, J. T.; Benditt, D. G.; DiMarco, J. P.; Fitzgerald, D.; Kowey, P. R.; Platia, E. V.; Schaal, S. F.; Shen, E.; Wesley, Jr; Windle, John Robert; Wood, M. A.

In: American Heart Journal, Vol. 135, No. 6 I, 01.01.1998, p. 1048-1054.

Research output: Contribution to journalArticle

Wood, MA, Stambler, BS, Ellenbogen, KA, Gilligan, DM, Perry, KT, Wakefield, LK, VanderLugt, JT, Benditt, DG, DiMarco, JP, Fitzgerald, D, Kowey, PR, Platia, EV, Schaal, SF, Shen, E, Wesley, J, Windle, JR & Wood, MA 1998, 'Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease', American Heart Journal, vol. 135, no. 6 I, pp. 1048-1054. https://doi.org/10.1016/S0002-8703(98)70071-7
Wood MA, Stambler BS, Ellenbogen KA, Gilligan DM, Perry KT, Wakefield LK et al. Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. American Heart Journal. 1998 Jan 1;135(6 I):1048-1054. https://doi.org/10.1016/S0002-8703(98)70071-7
Wood, M. A. ; Stambler, B. S. ; Ellenbogen, K. A. ; Gilligan, D. M. ; Perry, K. T. ; Wakefield, L. K. ; VanderLugt, J. T. ; Benditt, D. G. ; DiMarco, J. P. ; Fitzgerald, D. ; Kowey, P. R. ; Platia, E. V. ; Schaal, S. F. ; Shen, E. ; Wesley, Jr ; Windle, John Robert ; Wood, M. A. / Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. In: American Heart Journal. 1998 ; Vol. 135, No. 6 I. pp. 1048-1054.
@article{fb2b0aefe3a24c2eb70baea8c6e63648,
title = "Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease",
abstract = "Background: Recent studies suggest that class III antiarrhythmic agents may have enhanced efficacy in the treatment of ventricular tachycardia. This study describes the first clinical assessment of the new class III agent ibutilide to suppress inducible monomorphic ventricular tachycardia (VT) in human beings. Methods and Results: Fifty-five patients with coronary artery disease and inducible sustained monomorphic VT at baseline received either low (0.005 mg/kg + 0.001 mg/kg, load and maintenance infusion, respectively), middle (0.01 mg/kg + 0.002 mg/kg), or high dose (0.02 mg/kg + 0.004 mg/kg) infusions of ibutilide followed by repeat programmed ventricular stimulation. The mean age of the study group was 65.5 ± 9.5 years and mean left ventricular ejection fraction was 36{\%} ± 11{\%}. Of 48 evaluable patients, 21 (44{\%}) were rendered noninducible after ibutilide, with no difference in efficacy among the three dosing groups (p = 0.83). Ventricular effective refractory periods, QTc interval, and ventricular monophasic action potential duration were prolonged over baseline at all tested cycle lengths. The QTc and action potential prolongation were dose related. Serious drug-related adverse reactions included sustained polymorphic VT in two patients (3.6{\%}), spontaneous monomorphic VT in one patient (1.8{\%}), heart block in one patient (1.8{\%}), and hypotension in one patient (1.8{\%}). Conclusions: Ibutilide prolongs ventricular repolarization in human beings and demonstrates efficacy in suppressing inducible monomorphic VT. Significant cardiovascular side effects occurred in 12.7{\%} of patients.",
author = "Wood, {M. A.} and Stambler, {B. S.} and Ellenbogen, {K. A.} and Gilligan, {D. M.} and Perry, {K. T.} and Wakefield, {L. K.} and VanderLugt, {J. T.} and Benditt, {D. G.} and DiMarco, {J. P.} and D. Fitzgerald and Kowey, {P. R.} and Platia, {E. V.} and Schaal, {S. F.} and E. Shen and Jr Wesley and Windle, {John Robert} and Wood, {M. A.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0002-8703(98)70071-7",
language = "English (US)",
volume = "135",
pages = "1048--1054",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "6 I",

}

TY - JOUR

T1 - Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease

AU - Wood, M. A.

AU - Stambler, B. S.

AU - Ellenbogen, K. A.

AU - Gilligan, D. M.

AU - Perry, K. T.

AU - Wakefield, L. K.

AU - VanderLugt, J. T.

AU - Benditt, D. G.

AU - DiMarco, J. P.

AU - Fitzgerald, D.

AU - Kowey, P. R.

AU - Platia, E. V.

AU - Schaal, S. F.

AU - Shen, E.

AU - Wesley, Jr

AU - Windle, John Robert

AU - Wood, M. A.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Background: Recent studies suggest that class III antiarrhythmic agents may have enhanced efficacy in the treatment of ventricular tachycardia. This study describes the first clinical assessment of the new class III agent ibutilide to suppress inducible monomorphic ventricular tachycardia (VT) in human beings. Methods and Results: Fifty-five patients with coronary artery disease and inducible sustained monomorphic VT at baseline received either low (0.005 mg/kg + 0.001 mg/kg, load and maintenance infusion, respectively), middle (0.01 mg/kg + 0.002 mg/kg), or high dose (0.02 mg/kg + 0.004 mg/kg) infusions of ibutilide followed by repeat programmed ventricular stimulation. The mean age of the study group was 65.5 ± 9.5 years and mean left ventricular ejection fraction was 36% ± 11%. Of 48 evaluable patients, 21 (44%) were rendered noninducible after ibutilide, with no difference in efficacy among the three dosing groups (p = 0.83). Ventricular effective refractory periods, QTc interval, and ventricular monophasic action potential duration were prolonged over baseline at all tested cycle lengths. The QTc and action potential prolongation were dose related. Serious drug-related adverse reactions included sustained polymorphic VT in two patients (3.6%), spontaneous monomorphic VT in one patient (1.8%), heart block in one patient (1.8%), and hypotension in one patient (1.8%). Conclusions: Ibutilide prolongs ventricular repolarization in human beings and demonstrates efficacy in suppressing inducible monomorphic VT. Significant cardiovascular side effects occurred in 12.7% of patients.

AB - Background: Recent studies suggest that class III antiarrhythmic agents may have enhanced efficacy in the treatment of ventricular tachycardia. This study describes the first clinical assessment of the new class III agent ibutilide to suppress inducible monomorphic ventricular tachycardia (VT) in human beings. Methods and Results: Fifty-five patients with coronary artery disease and inducible sustained monomorphic VT at baseline received either low (0.005 mg/kg + 0.001 mg/kg, load and maintenance infusion, respectively), middle (0.01 mg/kg + 0.002 mg/kg), or high dose (0.02 mg/kg + 0.004 mg/kg) infusions of ibutilide followed by repeat programmed ventricular stimulation. The mean age of the study group was 65.5 ± 9.5 years and mean left ventricular ejection fraction was 36% ± 11%. Of 48 evaluable patients, 21 (44%) were rendered noninducible after ibutilide, with no difference in efficacy among the three dosing groups (p = 0.83). Ventricular effective refractory periods, QTc interval, and ventricular monophasic action potential duration were prolonged over baseline at all tested cycle lengths. The QTc and action potential prolongation were dose related. Serious drug-related adverse reactions included sustained polymorphic VT in two patients (3.6%), spontaneous monomorphic VT in one patient (1.8%), heart block in one patient (1.8%), and hypotension in one patient (1.8%). Conclusions: Ibutilide prolongs ventricular repolarization in human beings and demonstrates efficacy in suppressing inducible monomorphic VT. Significant cardiovascular side effects occurred in 12.7% of patients.

UR - http://www.scopus.com/inward/record.url?scp=19244381060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244381060&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(98)70071-7

DO - 10.1016/S0002-8703(98)70071-7

M3 - Article

VL - 135

SP - 1048

EP - 1054

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 6 I

ER -